pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,225 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT800Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace70raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Male puberty is understudied — but when it starts may predict long-term health risks
    Due to a significant gender gap, far less is known about the health risks of early or late puberty onset among boys than girls.
    STAT · 1mo ago↗ source
  • What happens at a longevity festival?
    What happens at a longevity festival? On this week's STATus Report, Alex Hogan gets a dispatch from STAT's Sarah Todd.
    STAT · 1mo ago↗ source
  • Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
    An oncologist shares three lessons from the world’s first randomized trial on a multi-cancer early detection.
    STAT · 1mo ago↗ source
← prev
page 25 of 49
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise
    “One of the cancer community’s worst fears is coming to pass,” writes Gwen Nichols of Blood Cancer United.
    STAT · 1mo ago↗ source
  • STAT+: After hospitals, patients get a turn to bring AI into the doctor’s office
    Ambient scribes were the first large-scale application of AI in health care. Now developers are pitching them as diligent note-takers for patients.
    STAT · 1mo ago↗ source
  • A Spanish biotech banks $87M to make differentiated ADCs
    Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Trump administration to strip job protections of top NIH officials, grants staff
    Among the affected positions, which the White House estimates to be 8,000, are high-level officials who oversee research grants from the NIH.
    STAT · 1mo ago↗ source
  • STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
    Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.
    STAT · 1mo ago↗ source
  • STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading data
    Highmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.
    STAT · 1mo ago↗ source
  • Legend surges on early data for ‘in vivo’ lymphoma cell therapy
    Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
    BioPharma Dive · 1mo ago↗ source
  • House bill aims to crack down on China biotech deals
    A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.
    BioPharma Dive · 1mo ago↗ source
  • NewLimit’s $435M megaround; Lilly’s busy dealmaking week
    The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health care
    In this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.
    STAT · 1mo ago↗ source
  • STAT+: Legend Biotech emerged as a rare market winner
    New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
    Taking weight loss drugs for at least three years could prevent thousands of knee replacements a year, a new study found
    STAT · 1mo ago↗ source
  • Is the military fueling eating disorders?
    A brief hantavirus update, some good news about death, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Lilly, Ascidian link up in RNA exon editing pact
    Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.
    BioPharma Dive · 1mo ago↗ source
  • Top ultra-processed food researchers call for sweeping policy change: ‘The system is rigged’
    A survey finds that ultra-processed foods are a cross-partisan concern. And yet policy has been slow to follow.
    STAT · 1mo ago↗ source
  • Opinion: The medical-billing AI arms race between providers and insurance
    “The financial side effects of care have become clinical ones,” writes Darshak Sanghavi.
    STAT · 1mo ago↗ source
  • Opinion: The Amish way of health care
    “Public health is going to have to talk about the Amish more and more”: Listen to STAT’s "First Opinion Podcast" on the Amish and health care.
    STAT · 1mo ago↗ source
  • Opinion: How the military may be fueling eating disorders in men
    “Much of the rhetoric, imagery, and policy messaging from the Trump administration centers on extreme masculine ideals,” First Opinion author writes.
    STAT · 1mo ago↗ source
  • STAT+: NIH cuts weakened network primed to respond to outbreaks like Ebola
    While NIH-funded centers weren’t on the front lines of virus responses like the CDC or USAID, some researchers involved in the network said the cuts have damaged relationships with experts…
    STAT · 1mo ago↗ source
  • STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients
    Advocates were already dreading Medicaid's work requirements. New rules are worse than they feared.
    STAT · 1mo ago↗ source
  • Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S.
    A senior NIH scientist and his research fellow were charged with smuggling vials of deactivated mpox virus into the country from Africa and lying about it.
    STAT · 1mo ago↗ source
  • Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
    Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
    BioPharma Dive · 1mo ago↗ source